Cannabinoids in the management of difficult to treat pain

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 245-259

  Russo, Ethan B ^a,b  

^a Porton Down Science Park   (United Kingdom)

^b NONE   (United States)

Author keywords

Analgesia; Cannabidiol; Cannabinoids; Multiple sclerosis; Pain management; Tetrahydrocannabinol

Indexed keywords

ACETYLSALICYLIC ACID; AJULEMIC ACID; ALPHA TOCOPHEROL; APIGENIN; ASCORBIC ACID; CANNABICHROMENE; CANNABIDIOL; CANNABIGEROL; CANNABINOID; CANNABIS; CANNAFLAVIN A; CARYOPHYLLENE; DRONABINOL; ENDORPHIN; ENKEPHALIN; MYRCENE; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIMONABANT; SITOSTEROL; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR;

AGITATION; AIRWAY OBSTRUCTION; ANALGESIA; ANALGESIC ACTIVITY; ANTIEMETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANXIETY; APPETITE; ATTENTION DISTURBANCE; BURNING MOUTH SYNDROME; CANCER PAIN; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COGNITION; CONFUSION; DISORIENTATION; DIZZINESS; DOPAMINERGIC ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPHORIA; EDEMA; EUPHORIA; FATIGUE; FIBROMYALGIA; HEART PALPITATION; HUMAN; HYPERALGESIA; HYPOTHERMIA; INFLAMMATION; INSOMNIA; INTOXICATION; INTRAOCULAR DRUG ADMINISTRATION; INTRAOCULAR PRESSURE; LETHARGY; LEUKOCYTE COUNT; MOUTH DISCOMFORT; MULTIPLE SCLEROSIS; NAUSEA; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN; PANIC; PARANOIA; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SMOKING; TACHYCARDIA; TASTE DISORDER; TREATMENT DURATION; TREATMENT INDICATION; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

EID: 41549121013     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (157)

1. ABC News, USA Today, Stanford Medical Center Poll. 2005. Broad experience with pain sparks search for relief [online]. URL: http://abcnews.go.com/images/Politics/979a1TheFightAgainstPain-pdf.
2. Abrams DI, Hilton JF, Leiser RJ, et al. 2003. Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placbo-controlled clinical trial. Ann Intern Med, 139:258-66.
3. Abrams DI, Jay CA, Shade SB, et al. 2007. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology, 68:515-21.
4. Agarwal N, Pacher P, Tegeder I, et al. 2007. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci, 10:870-9.
5. Akerman S, Holland PR, Goadsby PJ. 2007. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther, 320:64-71.
6. Akerman S, Kaube H, Goadsby PJ. 2003. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther, 309:56-63.
7. Akerman S, Kaube H, Goadsby PJ. 2004. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol, 142:1354-60.
8. Attal N, Brasseur L, Guirimand D, et al. 2004. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain, 8:173-7.
9. Banerjee SP, Snyder SH, Mechoulam R. 1975. Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J Pharmacol Exp Ther, 194:74-81.
10. Barnes MP. 2006. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother, 7:607-15.
11. Barrett ML, Scutt AM, Evans FJ. 1986. Cannflavin A and B, prenylated flavones from Cannabis sativa L. Experientia, 42:452-3.
12. Basile AC, Sertie JA, Freitas PC, et al. 1988. Anti-inflammatory activity of oleoresin from Brazilian Copaifera. J Ethnopharmacol, 22:101-9.
13. Beaulieu P. 2006. Effects of nabilone, a synthetic cannabinoid, on postoperative pain: (Les effets de la nabilone, un cannabinoide synthetique, sur la douleur postoperatoire]. Can J Anaesth, 53:769-75.
14. Berlach DM, Shir Y, Ware MA. 2006. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med, 7:25-9.
15. Berman JS, Symonds C, Birch R. 2004. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain, 112:299-306.
16. Bisogno T, Hanus L, De Petrocellis L, et al. 2001. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol, 134:845-52.
17. Blake DR, Robson P, Ho M, Jubb RW, et al. 2006. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford), 45:50-2.
18. British Medical Association. 1997. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers. 142 p.
19. Broom SL, Sufka KJ, Elsohly MA, et al. 2001. Analgesic and reinforcing proerties of delta9-THC-hemisuccinate in adjuvant-arthritic rats. Journal of Cannabis Therapeutics, 1:171-82.
20. Budney AJ, Hughes JR, Moore BA, et al. 2004. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry, 161:1967-77.
21. Buggy DJ, Toogood L, Maric S, et al. 2003. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain, 106:169-72.
22. Burstein S, Levin E, Varanelli C. 1973. Prostaglandins and cannabis. II. Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochem Pharmacol, 22:2905-10.
23. Cabral G. 2001. Immune system. In: Russo EB, Grotenhermen F eds. Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential. Binghamton, NY: Haworth Press. p 279-87.
24. Calhoun SR, Galloway GP, Smith DE. 1998. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs, 30:187-96.
25. Campbell FA, Tramber MR, Carroll D, et al. 2001. Are cannabinoids an effective and safe option in the management of pain? A qualitative systematic review. BMJ, 323:1-6.
26. Carrier EJ, Auchainpach JA, Hillard CJ. 2006. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA, 103:7895-900.
27. Challapalli PV, Stinchcomb AL. 2002. In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. Int J Pharm, 241:329-39.
28. Cichewicz DL, Martin ZL, Smith FL, et al. 1999. Enhancement of mu opioid antinociception by oral delta9-tetrahydrocannabinol: Dose-response analysis and receptor identification. J Pharmacol Exp Ther, 289:859-67.
29. Cichewicz DL, McCarthy EA. 2003. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther, 304:1010-5.
30. Cichewicz DL, Welch SP. 2003. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther, 305:812-7.
31. Clark P, Altman D. 2006. Assessment of blinding in Phase III Sativex spasticity studies. GW Pharmaceuticals. 56 p.
32. Clermont-Gnamien S, Atlani S, Attal N, et al. 2002. Utilisation thérapeutique du delta-9-tétrahydrocannabinol (dronabinol) dans les douleurs neuropathiques réfractaires. [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain]. Presse Med, 31(39 Pt 1):1840-5.
33. Davis WM, Hatoum NS. 1983. Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. Gen Pharmacol, 14:247-52.
34. de Meijer E. 2004. The breeding of cannabis cultivars for pharmaceutical end uses. In: Guy GW, Whittle BA, Robson P eds. Medicinal uses of cannabis and cannabinoids. London: Pharmaceutical Press. p 55-70.
35. Degenhardt L, Hall W, Lynskey M. 2003. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend, 71:37-48.
36. Devane WA, Hanus L, Breuer A, et al. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258:1946-9.
37. Di Marzo V, Melck D, Bisogno T, et al. 1998. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci, 21:521-8.
38. Dogrul A, Gul H, Akar A, et al. 2003. Topical cannabinoid antinociception: synergy with spinal sites. Pain, 105:11-6.
39. Dyson A, Peacock M, Chen A, et al. 2005. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain, 116:129-37.
40. ElSohly MA, Ross SA, Mehmedic Z, et al. 2000. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci, 45:24-30.
41. Ernst G, Denke C, Reif M, et al. 2005. Standardized cannabis extract in the treatment of postherpetic neuralgia: a randomized, double-blind, placebo-controlled cross-over study; 2005 September 9; Leiden, Netherlands. International Association for Cannabis as Medicine.
42. Evans FJ. 1991. Cannabinoids: The separation of central from peripheral effects on a structural basis. Planta Med, 57:S60-7.
43. Fimiani C, Liberty T, Aquirre AJ, et al. 1999. Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Prostaglandins Other Lipid Mediat, 57:23-34.
44. Fishman SM. 2006. Pain and politics: DEA, Congress, and the courts, oh my! Pain Med, 7:87-8.
45. Fitzgerald GA. 2004. Coxibs and cardiovascular disease. N Engl J Med, 351:1709-11.
46. Food and Drug Administration. 2004. Guidance for industry: Botanical drug products. In: Services UDoHaH, ed. US Government, p 48.
47. Fox A, Kesingland A, Gentry C, et al. 2001. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain, 92:91-100.
48. Fride E, Russo EB. 2006. Neuropsychiatry: Schizophrenia, depression, and anxiety. In: Onaivi E, Sugiura T, Di Marzo V eds. Endocannabinoids: The brain and body's marijuana and beyond. Boca Raton, FL: Taylor and Francis. p 371-82.
49. Frondini C, Lanfranchi G, Minardi M, et al. 2007. Affective, behavior and cognitive disorders in the elderly with chronic musculoskelatal pain: the impact on an aging population. Arch Gerontol Geriatr, 44(Suppl 1): 167-71.
50. Gaoni Y, Mechoulam R. 1964. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc, 86:1646-7.
51. Gauson LA, Stevenson LA, Thomas A, et al. 2007. Cannabigerol behaves as a partial agonist at both CB1 and CB2 receptors. 17th Annual Symposium on the Cannabinoids. Saint-Sauveur, Quebec, Canada: International Cannabinoid Research Society. p 206.
52. Gerritsen ME, Carley WW, Ranges GE, et al. 1995. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am J Pathol, 147:278-92.
53. Gertsch J, Raduner S, Leonti M, et al. 2007. Screening of plant extracts for new CB2-selective agonists revewals new players in Cannabis sativa. 17th Annual Symposium on the Cannabinoids. Saint-Sauveur, Quebec, Canada: International Cannabinoid Research Society. p 213.
54. Gibson SJ. 2007. IASP global year against pain in older persons: highlighting the current status and future perspectives in geriatric pain. Expert Rev Neurother, 7:627-35.
55. Gieringer D, St. Laurent J, Goodrich S. 2004. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. Journal of Cannabis Therapeutics, 4:7-27.
56. Gil ML, Jimenez J, Ocete MA, et al. 1989. Comparative study of different essential oils of Bupleurum gibraltaricum Lamarck. Pharmazie, 44:284-7.
57. Gomez MA, Saenz MT, Garcia MD, et al. 1999. Study of the topical anti-inflammatory activity of Achillea ageratum on chronic and acute inflammation models. Z Naturforsch [C], 54:937-41.
58. Gorter RW, Butorac M, Cobian EP, et al. 2005. Medical use of cannabis in the Netherlands. Neurology, 64:917-9.
59. Grinspoon L, Bakalar JB. 1997. Marihuana, the forbidden medicine. New Haven: Yale University Press. xv, 296 p.
60. Grotenhermen F. 2003. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet, 42:327-60.
61. Grotenhermen F. 2004. Cannabinoids for therapeutic use: designing systems to increase efficacy and reliability. American Journal of Drug Delivery, 2:229-40.
62. Grotenhermen F, Leson G, Berghaus G, et al. 2005. Developing science-based per se limits for driving under the influence of cannabis (DUIC). Findings and recommendations by an expert panel. Hürth, Germany: Nova- Institut. 49 p.
63. Guy GW, Robson P. 2003. A Phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK02125). Journal of Cannabis Therapeutics, 3:121-52.
64. Hampson AJ, Grimaldi M, Axelrod J, et al. 1998. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA, 95:8268-73.
65. Hazekamp A, Ruhaak R, Zuurman L, et al. 2006. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci, 95:1308-17.
66. Herkenham M, Lynn AB, Little MD, et al. 1990. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA, 87:1932-6.
67. Hohmann AG, Briley EM, Herkenham M. 1999. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res, 822:17-25.
68. Hohmann AG, Martin WJ, Tsou K, et al. 1995. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci, 56:2111-8.
69. Hohmann AG, Suplita RL, Bolton NM, et al. 2005. An endocannabinoid mechanism for stress-induced analgesia. Nature, 435:1108-12.
70. Holdcroft A, Maze M, Dore C, et al. 2006. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology, 104:1040-6.
71. Howlett AC, Johnson MR, Melvin LS, et al. 1988. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol, 33:297-302.
72. Huestis MA, Henningfield JE, Cone EJ. 1992. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol, 16:276-82.
73. Janse AFC, Breekveldt-Postma NS, Erkens JA, et al. 2004. Medicinal gebruik van cannabis.: PHARMO Instituut (Institute for Drug Outcomes Research]. 51 p.
74. Johnson JR, Potts R. 2005. Cannabis-based medicines in the treatment of cancer pain: a randomised, double-blind, parallel group, placebo controlled, comparative study of the efficacy, safety and tolerability of Sativex and Tetranabinex in patients with cancer-related pain.; 2005 March 8-11; Edinburgh, Scotland.
75. Jones RT, Benowitz N, Bachman J. 1976. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci, 282:221-39.
76. Joy JE, Watson SJ, Benson JA Jr. 1999. Marijuana and medicine: Assessing the science base. Washington, DC: Institute of Medicine.
77. Karsak M, Gaffal E, Date R, et al. 2007. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science, 316:1494-7.
78. Karst M, Salim K, Burstein S, et al. 2003. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA, 290:1757-62.
79. Katona S, Kaminski E, Sanders H, et al. 2005. Cannabinoid influence on cytokine profile in multiple sclerosis. Clin Exp Immunol, 140:580-5.
80. King LA, Carpentier C, Griffiths P. 2005. Cannabis potency in Europe. Addiction, 100:884-6.
81. Ko MC, Woods JH. 1999. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. Psychopharmacology (Berl), 143:322-6.
82. Kogan NM. 2005. Cannabinoids and cancer. Mini Rev Med Chem, 5:941-52.
83. Lemberger L, Rubin A, Wolen R, et al. 1982. Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev, 9(Suppl B): 17-23.
84. Li J, Daughters RS, Bullis C, et al. 1999. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain, 81:25-33.
85. Ligresti A, Moriello AS, Starowicz K, et al. 2006. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther, 318:1375-87.
86. Liu J, Li H, Burstein SH, Zurier RB, et al. 2003. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol, 63:983-92.
87. Lorenzetti BB, Souza GE, Sarti SJ, et al. 1991. Myrcene mimics the peripheral analgesic activity of lemongrass tea. J Ethnopharmacol, 34:43-8.
88. Lynch ME, Young J, Clark AJ. 2006. A case series of patients using medicinal marihuana for management of chronic pain under the Canadian Marihuana Medical Access Regulations. J Pain Symptom Manage, 32:497-501.
89. Mackie K. 2006. Cannabinoid receptors as therapeutic targets. Ann Rev Pharmacol Toxicol, 46:101-22.
90. Maida V. 2007, The synthetic cannabinoid nabilone improves pain and symptom management in cancer patietns. Breast Cancer Res Treat, 103:121-2.
91. Malfait AM, Gallily R, Sumariwalla PF, et al. 2000. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA, 97:9561-6.
92. Manzanares J, Corchero J, Romero J, et al. 1998. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res, 55:126-32.
93. Martin WJ, Hohmann AG, Walker JM. 1996. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects. J Neurosci, 16:6601-11.
94. Massa F, Monory K. 2006. Endocannabinoids and the gastrointestinal tract. J Endocrinol Invest, 29(3 Suppl):47-57.
95. McPartland JM, Russo EB. 2001. Cannabis and cannabis extracts: Greater than the sum of their parts? Journal of Cannabis Therapeutics, 1:103-32.
96. Mechoulam R, Ben-Shabat S, Hanus L, et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol, 50:83-90.
97. Mehmedic Z, Martin J, Foster S, et al. Delta-9-THC and other cannabinoids content of confiscated marijuana: potency trends, 1993-2003.; 2005 September 10; Leiden, Netherlands. International Association of Cannabis as Medicine.
98. Müller-Vahl KR, Schneider U, Kolbe H, et al. 1999. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry, 156:495.
99. Munro S, Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365:61-5.
100. Nadulski T, Pragst F, Weinberg G, et al. 2005a. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit, 27:799-810.
101. Nadulski T, Sporkert F, Schnelle M, et al. 2005b. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. J Anal Toxicol, 29:782-9.
102. Neff GW, O'Brien CB, Reddy KR, et al. 2002. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol, 97:2117-9.
103. Nicholson AN, Turner C, Stone BM, et al. 2004. Effect of deita-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol, 24:305-13.
104. Nicolodi M, Volpe AR, Sicuteri F. 1998. Fibromyalgia and headache. Failure of serotonergic analgesia and N-methyl-D-aspartate-mediated neuronal plasticity: Their common clues. Cephalalgia, 18(Suppl 21):41-4.
105. Notcutt W, Price M, Chapman G. 1997. Clinical experience with nabilone for chronic pain. Pharmaceutical Sciences, 3:551-5.
106. Notcutt W, Price M, Miller R, et al. 2004. Initial experiences with medicinal extracts of cannabis for chronic pain: resul ts from 34 "N of 1" studies. Anaesthesia, 59:440-52.
107. Nurmikko TJ, Serpell MG, Hoggart B, et al. 2007. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. In press.
108. Pacher P, Batkai S, Kunos G. 2006. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev, 58:389-462.
109. Pate D. 1994. Chemical ecology of cannabis. Journal of the International Hemp Association, 2:32-7.
110. Pérez J. 2006. Combined cannabinoid therapy via na oromucosal spray. Drugs Today (Barc), 42:495-501.
111. Pertwee RG. 2005. Cannabidiol as a potential medicine. In: Mechoulam R ed. Cannabinoids as therapeutics. Basel, Switzerland: Birkhäuser Verlag. p 47-65.
112. Pope HG Jr, Gruber AJ, Hudson JI, et al. 2001. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry, 58:909-15.
113. Rahn EJ, Makriyannis A, Hohmann AG. 2007. Activation of cannabinoid CB(1) and CB(2) receptors suppresses neuropathic; nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol, 1-13.
114. Rao VS, Menezes AM, Viana GS. 1990. Effect of myrcene on nociception in mice. J Pharm Pharmacol, 42:877-8.
115. Re L, Barocci S, Sonnino S, et al. 2000. Linalool modifies the nicotinic receptor-ion channel kinetics at the mouse neuromuscular junction. Pharmacol Res, 42:177-82.
116. Richardson JD, Aanonsen L, Hargreaves KM. 1997. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol, 319:R3-4.
117. Richardson JD, Aanonsen L, Hargreaves KM. 1998a. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol, 345:145-53.
118. Richardson JD, Aanonsen L, Hargreaves KM. 1998b. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci, 18:451-7.
119. Richardson JD, Kilo S, Hargreaves KM. 1998c. Cannabinoids; reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain, 75:111-9.
120. Rog DJ, Nurmiko T, Friede T, et al. 2005. Randomized controlled trial of cannabis based medicine in central neuropathic pain due to multiple sclerosis. Neurology, 65:812-19.
121. Russo E. 1998. Cannabis for migraine treatment: The once and future prescription? An historical and scientific review. Pain, 76:3-8.
122. Russo EB. 2001. Hemp for headache: An in-depth historical and scientific review of cannabis in migraine treatment. Journal of Cannabis Therapeutics, 1:21-92.
123. Russo EB. 2004. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett, 25:31-9.
124. Russo EB. 2006a. The role of cannabis and cannabinoids in pain management. In: Cole BE, Boswell M eds. Weiner's Pain Management: A Practical Guide for Clinicians. 7th ed. Boca Raton, FL: CRC Press. p 823-44.
125. Russo EB. 2006b. The solution to the medicinal cannabis problem. In: Schatman ME, ed. Ethical issues in chronic pain management. Boca Raton, FL: Taylor and Francis. p 165-194.
126. Russo EB, Guy GW 2006. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses, 66:234-46.
127. Russo EB, Guy GW, Robson PJ. 2007a. Cannabis, pain and sleep: lessons from therapeutic clinical trials of Sativex® cannabis based medicine. Chem Biodivers, 4:1729-43.
128. Russo EB, Mathre ML, Byme A, et al. 2002. Chronic cannabis use in the Compassionate Investigational New Drug Program: An examination of benefits and adverse effects of legal clinical cannabis. Journal of Cannabis Therapeutics, 2:3-57.
129. Samaha AN, Robinson TE. 2005. Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci, 26:82-7.
130. Sarchielli P, Pini LA, Coppola F, et al. 2007. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology, 32:1384-90.
131. Schaefer CF, Brackett DJ, Gunn CG, et al. 1979. Decreased platelet aggregation following marihuana smoking in man. J Okla State Med Assoc, 72:435-6.
132. Schley M, Legler A, Skopp G, et al. 2006. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin, 22:1269-76.
133. Shen M, Piser TM, Seybold VS, et al. 1996. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci, 16:4322-34.
134. Smith NT. 2002. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction, 97:621-32.
135. Solowij N, Stephens RS, Roffman RA, et al. 2002. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA, 287:1123-31.
136. Spadone C. 1991. Neurophysiologie du cannabis [Neurophysiology of cannabis]. Encephale, 17:17-22.
137. Stott CG, Ayerakwa L, Wright S, et al. 2007. Lack of human cytochrome P450 induction by Sativex. 17th Annual Symposium on the Cannabinoids. Saint-Sauveur, Quebec, Canada: International Cannabinoid Research Society. p 211.
138. Stott CG, Guy GW, Wright S, et al. 2005a.The effects of cannabis extracts Tetranabinex and Nabidiolex on human cyclo-oxygenase (COX) activity. June 2005; Clearwater, FL. International Cannabinoid Research Society.
139. Stott CG, Guy GW, Wright S, et al. 2005b. The effects of cannabis extracts Tetranabinex and Nabidiolex on human cytochrome P450-mediated metabolism. June 27 2005; Clearwater, FL. International Cannabinoid Research Association. p 163.
140. Strangman NM, Walker JM. 1999. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol, 82:472-7.
141. Svendsen KB, Jensen TS, Bach FW 2004. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ, 329:253.
142. Tambe Y, Tsujiuchi H, Honda G, et al. 1996. Gastric cytoprotection of the non-steroidal anti-inflammatory sesquiterpene, beta-caryophyllene. Planta Med, 62:469-70.
143. Tashkin DP. 2005. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis, 63:93-100.
144. Topol EJ. 2004. Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med, 351:1707-9.
145. Volfe Z, Dvilansky A, Nathan I. 1985. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res, 5:243-6.
146. Wade DT, Makela P, Robson P, et al. 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler, 10:434-41.
147. Wade DT, Makela PM, House H, et al. 2006. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler, 12:639-45.
148. Wade DT, Robson P, House H, et al. 2003. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil, 17:18-26.
149. Walker JM, Hohmann AG, Martin WJ, et al. 1999a. The neurobiology of cannabinoid analgesia. Life Sci, 65:665-73.
150. Walker JM, Huang SM, Strangman NM, et al. 1999b. Pain modulation by the release of the endogenous cannabinoid anandamide. Proc Nat Acad Sci USA, 96:12198-203.
151. Walker JM, Huang SM. 2002. Cannabinoid analgesia. Pharmacol Ther, 95:127-35.
152. Ware M, Wang W, Shapiro S, et al. 2007. Smoked cannabis for chronic neuropathic pain: results of a pilot study. 17th Annual Symposium on the Cannabinoids. Saint-Sauveur, Quebec, Canada: International Cannabinoid Research Society p31.
153. Wirth PW, Watson ES, ElSohly M, et al. 1980. Anti-inflammatory properties of cannabichromene. Life Sci, 26:1991-5.
154. Wright S. 2005. GWMS001 and GWMS0106: maintenance of blinding. London: GW Pharmaceuticals. 8 p.
155. Zajicek J, Fox P, Sanders H, et al. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet, 362:1517-26.
156. Zajicek JP, Sanders HP, Wright DE, et al. 2005. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry, 76:1664-9.
157. Zuardi AW, Guimaraes FS. 1997. Cannabidiol as an anxiolytic and antipsychotic. In: Mathre ML, editor. Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana. Jefferson, NC: McFarland. p 133-41.